A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Фаза 2 Завершено NCT04006145

Заболевание	NAFLD, NASH
Фаза	Фаза 2
Спонсор	Albireo
Статус	Завершено
Участники	47 участн.
Вмешательство	Elobixibat, Placebo oral tablet
Дата начала	6.06.2019
Дата завершения	26.06.2020
Публикация результатов	27.09.2021

Кратко

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)

Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16

Week 16 · "mmol/L"

Elobixibat	-0.57 ± 0.125 "mmol/L"
Placebo	-0.17 ± 0.134 "mmol/L"

p-value	0.029
LS-Means Difference	-0.40 (95% CI -0.76–-0.04)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский